Literature DB >> 14502253

Understanding the pathogenesis of myelodysplastic syndromes.

Michel Delforge1.   

Abstract

Myelodysplastic syndromes (MDS) are clonal disorders of an immature hematopoietic progenitor cell. MDS hematopoiesis is characterized by abnormal progenitor proliferation and impaired cellular differentiation and maturation. As a consequence, the majority of MDS patients have a gradual evolution towards progressive bone marrow failure and/or leukemic transformation. The efforts made by several research groups during the last few years have helped to unravel the complex underlying pathogenesis of MDS. In this review, we will focus on the principal cytogenetic and molecular abnormalities involved in MDS initiation and disease progression. Additionally, we will discuss the influence of the marrow microenvironment on survival and proliferation of hematopoietic progenitors in MDS.

Entities:  

Mesh:

Year:  2003        PMID: 14502253     DOI: 10.1038/sj.thj.6200315

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  7 in total

1.  Hematopoietic malignancies associated with viral and alcoholic hepatitis.

Authors:  Lesley A Anderson; Ruth Pfeiffer; Joan L Warren; Ola Landgren; Shahinaz Gadalla; Sonja I Berndt; Winnie Ricker; Ruth Parsons; William Wheeler; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10-28       Impact factor: 4.254

2.  Conditional random pattern model for copy number aberration detection.

Authors:  Fuhai Li; Xiaobo Zhou; Wanting Huang; Chung-Che Chang; Stephen T C Wong
Journal:  BMC Bioinformatics       Date:  2010-04-22       Impact factor: 3.169

3.  The cell growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS.

Authors:  Gordana Bogdanović; Dimitar Jakimov; Bratislav Stojiljkovic; Vladimir Jurisić
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  An association between hypoplastic myelodysplastic syndrome and T-prolymphocytic leukaemia.

Authors:  C A Arathi; K R Puttaraj; S N Shobha
Journal:  J Lab Physicians       Date:  2011-01

Review 5.  Farnesyltransferase inhibitors in myelodysplastic syndrome.

Authors:  E J Feldman
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 4.213

6.  Pattern-selection based power analysis and discrimination of low- and high-grade myelodysplastic syndromes study using SNP arrays.

Authors:  Xiaorong Yang; Xiaobo Zhou; Wan-Ting Huang; Lingyun Wu; Federico A Monzon; Chung-Che Chang; Stephen T C Wong
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

7.  Identification of SNP-containing regulatory motifs in the myelodysplastic syndromes model using SNP arrays and gene expression arrays.

Authors:  Jing Fan; Jennifer G Dy; Chung-Che Chang; Xiaobo Zhou
Journal:  Chin J Cancer       Date:  2013-01-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.